|
| Tuesday, October 4, 2016 |
|
|
エーザイとキョーリン製薬HD、タイで過活動膀胱治療剤「ウリトス錠」を発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）およびキョーリン製薬ホールディングス株式会社（本社：東京都、代表取締役社長：穂川稔）は、このたび、エーザイのタイ販売子会社 Eisai(Thailand) Marketing Co., Ltd.が、過活動膀胱治療剤「ウリトス(R)錠」（一般名：イミダフェナシン）を現地にて新発売したことを発表しました。 more info >> |
|
|
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A. |
| Eisai Co., Ltd. announced today that its research subsidiary Morphotek, Inc. has signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. to develop and commercialize the monoclonal antibody farletuzumab as a potential anticancer agent in Latin America. more info >> |
|
|
Launch of Uritos Tablets for Overactive Bladder in Thailand |
| Eisai Co., Ltd. and KYORIN Holdings, Inc. announced today that Eisai's Thai subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched Uritos Tablets (generic name: imidafenacin), a therapeutic agent for overactive bladder, in Thailand. more info >> |
|
|
エーザイ、米国で肥満症治療剤「BELVIQ(R)」の新剤形1日1回製剤「BELVIQ XR」を発売 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社の米国子会社であるエーザイ・インクが肥満症治療剤「BELVIQ(R)」 (一般名：lorcaserin hydrochloride）の新剤形である1日1回製剤「BELVIQ XR(R)」を、米国において新発売しましたのでお知らせします。 more info >> |
|
|
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched BELVIQ XR 20mg tablets, a new once-daily formulation of BELVIQ (generic name: lorcaserin hydrochloride) for chronic weight management in the United States. more info >> |
|
| Friday, September 30, 2016 |
|
|
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced ienttoday the initiation of a global Phase III Clinical Study (Study 307, CLEAR Study) of its in-house developed multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (lenvatinib) in respective combination regimens with the anticancer agent everolimus and the anti-PD-1 antibody pembrolizumab as a potential first-line treatment for advanced renal cell carcinoma. more info >> |
|
|
エーザイ、抗がん剤「レンバチニブ」の進行性腎細胞がん一次治療対象の臨床第III相試験を開始 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製のマルチキナーゼ阻害剤レンバチニブメシル酸塩と抗がん剤エベロリムスまたは抗PD-1抗体ペムブロリズマブとの2つの併用療法に関して、進行性腎細胞がんの一次治療を対象としたグローバル臨床第III相試験（307試験、CLEAR試験）を開始することをお知らせします。 more info >> |
|
| Thursday, September 29, 2016 |
|
|
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016 |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical and pre-clinical data on lenvatinib mesylate and eribulin mesylate will be presented during the European Society for Medical Oncology (ESMO) Congress 2016 more info >> |
|
| Wednesday, September 28, 2016 |
|
|
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis |
| AbbVie GK and Eisai Co., Ltd. today announced the additional approval for a new indication of HUMIRA, a fully human anti-TNF-alha monoclonal antibody formulation, in the treatment of non-infectious intermediate, posterior and panuveitis. more info >> |
|
|
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan |
| Eisai Co., Ltd. announced today that it has commenced provision of the "EMILY" smartphone app in Japan to enable people with epilepsy and their families to enjoy greater peace of mind. more info >> |
|
|
|
|
